ONKURE THERAPEUTICS INC

ONKURE THERAPEUTICS’ insider options reveal Manke Isaac’s disciplined, long‑term stake strategy—boosting confidence while offering liquidity insights for investors.

OnKure Therapeutics’ CEO buys 330,000 options, a move that signals executive confidence and aligns incentives with upcoming clinical milestones, hinting at potential upside for investors.